| Literature DB >> 32260297 |
Nhan Trong Le1, Duc Viet Ho1, Tuan Quoc Doan1, Anh Tuan Le2, Ain Raal3, Donatella Usai4, Silvia Madeddu5, Mauro Marchetti6, Marianna Usai7, Paola Rappelli4, Nicia Diaz4, Stefania Zanetti4, Hoai Thi Nguyen1, Piero Cappuccinelli4, Matthew Gavino Donadu4,7.
Abstract
:The present study aimed to determine the antimicrobial activity and chemical composition of leaves-extracted essential oil of Leoheo domatiophorus Chaowasku, D.T. Ngo and H.T. Le (L. domatiophorus), including antibacterial, antimycotic, antitrichomonas and antiviral effects. The essential oil was obtained using hydrodistillation, with an average yield of 0.34 ± 0.01% (v/w, dry leaves). There were 52 constituents as identified by GC/MS with available authentic standards, representing 96.74% of the entire leaves oil. The essential oil was comprised of three main components, namely viridiflorene (16.47%), (-)-δ-cadinene(15.58%) and γ-muurolene (8.00%). The oil showed good antimicrobial activities against several species: Gram-positive strains: Staphylococcus aureus (two strains) and Enterococcus faecalis, with Minimum Inhibitory Concentration (MIC) and Minimum Lethal Concentration (MLC) values from 0.25 to 1% (v/v); Gram-negative strains such as Escherichia coli (two strains), Pseudomonas aeruginosa (two strains) and Klebsiella pneumoniae, with MIC and MLC values between 2% and 8% (v/v); and finally Candida species, having MIC and MLC between 0.12 and 4% (v/v).Antitrichomonas activity of the oil was also undertaken, showing IC50, IC90 and MLC values of 0.008%, 0.016% and 0.03% (v/v), respectively, after 48h of incubation. The essential oil resultedin being completely ineffective against tested viruses, ssRNA+ (HIV-1, YFV, BVDV, Sb-1, CV-B4), ssRNA- (hRSVA2, VSV), dsRNA (Reo-1), and dsDNA (HSV-1, VV) viruses with EC50 values over 100 µg/mL. This is the first, yet comprehensive, scientific report about the chemical composition and pharmacological properties of the essential oil in L. domatiophorus.Entities:
Keywords: antimicrobial activity; essential oil; new anti-infectious agents; phytochemicals
Year: 2020 PMID: 32260297 PMCID: PMC7237999 DOI: 10.3390/plants9040453
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Chemical composition of the essential oil from the leaves of L. domatiophorus.
| No. | RT | aKI | Components | b% ± SD | cIM | dReferences |
|---|---|---|---|---|---|---|
| 1 | 22.17 | 1003 | α-Phellandrene | 0.02 ± 0.01 | Std | |
| 2 | 22.75 | 1019 | α-Terpinene | 0.01 ± 0.01 | Std | |
| 3 | 23.17 | 1025 | m-Cymene | 0.03 ± 0.01 | Std | |
| 4 | 23.43 | 1028 | (+)-Limonene | 0.02 ± 0.01 | Std | |
| 5 | 23.56 | 1032 | β-Phellandrene | 0.01 ± 0.01 | Std | |
| 6 | 24.26 | 1035 | 0.01 ± 0.01 | Std | ||
| 7 | 27.37 | 1103 | Nonanal | 0.02 ± 0.01 | Std | |
| 8 | 31.44 | 1179 | Terpinen-4-ol | 0.02 ± 0.01 | Std | |
| 9 | 32.14 | 1189 | L-α-Terpineol | 0.01 ± 0.01 | Std | |
| 10 | 36.24 | 1274 | Phellandral | 0.03 ± 0.01 | MS | NIST |
| 11 | 39.90 | 1376 | α-Ylangene | 0.24 ± 0.02 | MS | NIST |
| 12 | 39.95 | 1378 | Isoledene | 0.38 ± 0.02 | MS | NIST |
| 13 | 40.13 | 1379 | α-Copaene | 1.01 ± 0.03 | Std | |
| 14 | 40.55 | 1384 | Z-β-Elemene | 0.22 ± 0.03 | Std | |
| 15 | 41.45 | 1413 | β-Maaliene | 0.40 ± 0.02 | MS-RI | [ |
| 16 | 41.72 | 1421 | 1.28 ± 0.04 | Std | ||
| 17 | 41.95 | 1423 | γ-Maaliene | 0.26 ± 0.01 | MS | NIST |
| 18 | 42.23 | 1441 | 0.51 ± 0.02 | MS | NIST | |
| 19 | 42.35 | 1440 | (+)-Aromadendrene | 3.82 ± 0.21 | MS | NIST |
| 20 | 42.47 | 1443 | Cedrane | 0.22 ± 0.01 | MS | NIST |
| 21 | 42.54 | 1451 | 0.51 ± 0.01 | MS | Adams | |
| 22 | 42.64 | 1451 | α-Himachalene | 0.21 ± 0.01 | MS | NIST |
| 23 | 42.79 | 1452 | 0.27 ± 0.01 | MS | Adams | |
| 24 | 42.88 | 1452 | α-Humulene | 0.44 ± 0.02 | Std | |
| 25 | 43.04 | 1463 | Alloaromadendrene | 0.74 ± 0.04 | MS | NIST |
| 26 | 43.40 | 1480 | γ-Muurolene | 8.00 ± 0.22 | MS | [ |
| 27 | 43.52 | 1480 | α-Muurolenediastereoisomer | 2.92 ± 0.11 | MS | NIST |
| 28 | 43.66 | 1484 | Germacrene D | 1.77 ± 0.11 | MS | Adams |
| 29 | 43.78 | 1493 | (-)-β-Cadinene | 1.20 ± 0.09 | MS | [ |
| 30 | 43.98 | 1496 | Ledene (Viridiflorene) | 16.47 ± 0.21 | MS-RI | [ |
| 31 | 44.08 | 1501 | α-Muurolene | 5.45 ± 0.12 | MS | [ |
| 32 | 44.24 | 1514 | (+)-δ-Cadinene | 1.31 ± 0.05 | Std | |
| 33 | 44.56 | 1514 | γ-Cadinene | 5.18 ± 0.11 | Std | |
| 34 | 44.67 | 1523 | (-)-δ-Cadinene | 15.58 ± 0.42 | MS | Adams |
| 35 | 44.78 | 1527 | 1.60 ± 0.07 | MS | NIST | |
| 36 | 44.83 | 1530 | Epizonarene | 0.90 ± 0.04 | MS-RI | [ |
| 37 | 45.08 | 1533 | Cada-1,4-diene | 0.96 ± 0.07 | MS-RI | [ |
| 38 | 45.20 | 1540 | α-Muurolenediastereoisomer | 1.82 ± 0.08 | MS | NIST |
| 39 | 45.36 | 1549 | α-Calacorene | 0.88 ± 0.04 | MS | NIST |
| 40 | 46.03 | 1568 | Epiglobulol | 1.00 ± 0.05 | MS | NIST |
| 41 | 46.28 | 1571 | Palustrol | 0.89 ± 0.04 | MS-RI | [ |
| 42 | 46.43 | 1578 | (+)-Spathulenol | 0.97 ± 0.04 | Std | |
| 43 | 46.71 | 1583 | Globulol | 3.10 ± 0.12 | MS | Adams |
| 44 | 46.95 | 1591 | Viridiflorol (Ledol) | 2.03 ± 0.11 | MS | NIST |
| 45 | 47.21 | 1599 | Rosifoliol | 1.79 ± 0.08 | MS | NIST |
| 46 | 47.66 | 1608 | Eudesmol<5epi-7-epi-α> | 1.09 ± 0.07 | MS | Adams |
| 47 | 47.70 | 1616 | Cubenol | 2.20 ± 0.09 | MS-RI | [ |
| 48 | 47.84 | 1619 | (-)-Spathulenol | 0.57 ± 0.04 | Std | |
| 49 | 48.04 | 1639 | α-epi-Cadinol | 1.65 ± 0.03 | Std | |
| 50 | 48.09 | 1640 | α-epi-Muurolol | 2.40 ± 0.12 | Std | |
| 51 | 48.13 | 1646 | (-)-δ-Cadinol | 0.73 ± 0.04 | Std | |
| 52 | 48.41 | 1654 | α-Cadinol | 3.59 ± 0.09 | Std | |
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
|
| |||||
|
|
|
Data are the mean of three replicates ± SD.aRetention index (Kovalts) relative to n-alkanes (C9–C22). b Percentage of compounds. Identification methods (IM): MS by comparison of the Mass spectrum with those of the computer mass libraries Adams, NIST 11 and by interpretation of the mass spectra fragmentations. RI by comparison of retention index with those reported in literature. Std by comparison of the retention time and mass spectrum of available authentic standards. Papers take as reference to compare the relative RI.
Antimicrobial activities (MIC and MLC) of essential oil from the leaves of L. domatiophorus.
| Strains | aMIC (% | bMLC (% |
|---|---|---|
|
| ||
| 0.25 | 0.5 | |
| 0.25 | 0.5 | |
| 1 | 1 | |
|
| ||
| 4 | 8 | |
| 2 | 4 | |
| 2 | 4 | |
| 4 | 4 | |
| 4 | 4 | |
|
| ||
| 4 | 4 | |
| 2 | 2 | |
| 1 | 1 | |
| 0.12 | 0.12 |
a MIC: Minimum Inhibitory Concentrations; b MLC: Minimum Lethal Concentrations.
In vitro anti-T.vaginalis activity of essential oil from the leaves of L. domatiophorus.
| Time | IC50 (% | IC90 (% | MLC (% |
|---|---|---|---|
|
| 1 | 2 | 4 |
|
| 0.12 | 0.25 | 0.5 |
|
| 0.016 | 0.03 | 0.06 |
|
| 0.008 | 0.016 | 0.03 |
IC: The concentration that causes 50% Trichomonas growth inhibition. IC The concentration that causes ≥ 90% Trichomonas growth inhibition. MLC: The concentration that causes the death of 100% Trichomonas.
Cytotoxicity and antiviral activity of essential oil from L. domatiophorus against representatives of ssRNA+ (HIV-1,YFV, BVDV, Sb-1, CV- B4), ssRNA− (hRSV A2, VSV), dsRNA (Reo-1), and dsDNA (HSV-1, VV) viruses.
| Cell Lines and Virus | MT4 | HIV-1IIIB | BHK-21 | YFV | Reo-1 | MDBK | BVDV | Vero-76 | hRSVA2 | VSV | HSV-1 | VV | Sb-1 | CV-B4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC50a | EC50b | CC50c | EC50d | EC50d | CC50e | EC50f | CC50g | EC50h | ||||||
| Oil | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
|
| ||||||||||||||
|
| 40 | 0.003 ± 0.0003 | - | - | - | - | - | - | - | - | - | - | - | - |
|
| - | - | 80 | 1.4 ± 0.2 | - | >100 | 1.7 ± 0.3 | - | - | - | - | - | - | - |
|
| - | - | - | - | - | - | - | >100 | - | - | - | - | 2 | 2 ±0.5 |
|
| - | - | - | - | - | - | - | ≥14 | 2 ± 0.2 | - | - | - | - | - |
|
| - | - | - | - | - | - | - | >100 | - | - | 3.0 ± 0.1 | - | - | - |
|
| - | - | - | - | - | - | - | 19 | - | - | - | 1.7 ± 0.1 | - | - |
|
| - | - | >100 | - | 17 | - | - | - | - | - | - | - | - | - |
Data represent mean values ŷ SD for three independent determinations. For values where SD is not shown, variation among duplicate samples was less than 15%. Oil: essential oil from the leaves of L. domatiophorus; RC1: Efavirenz; RC2: 2′-C-methylguanosine; RC3: Pleconaril; RC4: 6-aza-uridine; RC5: Acycloguanosine; RC6: Mycophenolic acid; RC7: 2′-C-methylcytidine; a compound concentration (µg mL−1) required to reduce the proliferation of mock-infected MT-4 cells by 50%, as determined by the MTT method. b Compound concentration (µg mL−1) required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity, as determined by the MTT method. c Compound concentration (µg mL−1) required to reduce the viability of mock-infected BHK-21 cells by 50%, as determined by the MTT method. d Compound concentration (µg mL−1) required to achieve 50% protection of BHK-21 cells from YFV or Reo-1 induced cytopathogenicity, as determined by the MTT method. e Compound concentration (µg mL−1) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method. f Compound concentration (µg mL−1) required to achieve 50% protection of MDBK cells from BVDV induced cytopathogenicity, as determined by the MTT method. g Compound concentration (µg mL−1) required to reduce the viability of mock-infected Vero-76 cells by 50%. as determined by the MTT method. h Compound concentration (µg mL−1) required to reduce the plaque number of hRSVA2, VSV, HSV-1, VV, Sb-1and CV-B4 by 50% in Vero-76 monolayers. * Reference Compds: CC50 and EC50 are in µM.